Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

This study tests a combination of pembrolizumab (an immunotherapy drug) and bendamustine (a chemotherapy drug) for classical Hodgkin lymphoma that has come back or is not responding to standard treatments. **You may be eligible if...** - You have a confirmed diagnosis of classical Hodgkin lymphoma that has relapsed or is refractory (not responding) - You have received at least one prior standard treatment - You are 18 or older and in adequate overall health - You have measurable disease on imaging **You may NOT be eligible if...** - You have had prior treatment with pembrolizumab or similar checkpoint inhibitor drugs - You have active autoimmune disease - You have significant heart, kidney, or liver problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.